PARP inhibitors in prostate cancer and the rationale behind combination treatment
PARP inhibitors in prostate cancer and the rationale behind combination treatment
A 2-part micro learning programme with videos and downloadable resources
A 2-part micro learning programme with videos and downloadable resources
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
In this micro learning programme, you'll learn about PARP inhibitors in prostate cancer from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno.
Learning resources include videos, slides, flashcards and assessments. Complete both modules to earn your CME credit.
What you'll learn
- Module 1 covers the use of PARP inhibitors as monotherapy in advanced prostate cancer
- Module 2 explains the rationale behind combination treatment with anti-androgens
Assoc. Prof. Alicia Morgans
Medical Oncologist
Dana-Farber Cancer Institute
United States (US)
Dr Pasquale Rescigno
Clinical Senior Lecturer
Newcastle University
United Kingdom (UK)
Module 1 - PARP inhibitors in advanced prostate cancer
Micro learning | 
4 min
|accreditation:
EACCME |
Jan 2023
download resources
I agree that this educational programme:
Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens
Micro learning | 4 min
|accreditation:
EACCME |
Jan 2023
download resources
I agree that this educational programme:
Clinical takeaways:
- PARP inhibitors are effective drugs as monotherapy in mCRPC patients with HRR alterations
- Genetic testing is important to help with treatment decision-making and for understanding inherited risk
- BRCA mutations are associated with poor outcomes in mCRPC patients
- Patients with tumours harbouring BRCA1/BRCA2 alterations appear to derive the greatest clinical benefit from PARPi, but patients with other HRR alterations also derive benefit
- PARP inhibitors combined with novel hormonal agents are effective as a first-line treatment option for mCRPC patients with an HRR mutation. Certain combinations, such as olaparib plus abiraterone, have also shown benefits in patients regardless of their HRR status
This PARP Inhibitors in Prostate Cancer micro e-learning programme is endorsed by 
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
17 min
Other programmes developed by Assoc. Prof. Alicia Morgans
Assoc. Prof. Alicia Morgans
Medical Oncologist
Dana-Farber Cancer Institute
United States (US)
